跳至主要内容
临床试验/EUCTR2015-001222-42-Outside-EU/EEA
EUCTR2015-001222-42-Outside-EU/EEA进行中(未招募)不适用

A double-blind trial comparing the efficacy, tolerability and safety of monotherapy topiramate versus phenytoin in subjects with seizures indicative of new onset epilepsy

Johnson & Johnson Pharmaceutical Research and Development, L.L.C.0 个研究点目标入组 261 人开始时间: 2015年4月24日最近更新:
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
261

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - Seizures indicative of new-onset epilepsy (or epilepsy relapse) of untreated epilepsy
  • - at least one but not more than 20 unprovoked seizures within past 3 months
  • - weighing more than 110 pounds
  • - considered to be a good candidate for rapid initiation of anti-seizure medication
  • - able to swallow a tablet whole (without crushing it).
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 262
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 262
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 262

排除标准

  • - Not having taken anti-seizure medications within the past 30 days
  • - no provoking factors for seizures (presence of alcohol withdrawal, drug intoxication, acute meningitis or encephalitis, acute head injury or stroke, acute hypoxic/ischemic encephalopathy, or brain tumor)
  • - no presence of active liver disease or serious kidney disease
  • - not pregnant or breast-feeding
  • - not using birth control.

研究者

发起方
Johnson & Johnson Pharmaceutical Research and Development, L.L.C.

相似试验